A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis

Multiple Sclerosis

Volumn 22, Issue 4, 2016, Pages 533-543

  Kuhle, J ^a,b,c   Hardmeier, M ^a   Disanto, G ^b,c   Gugleta, K ^a   Ecsedi, M ^a   Lienert, C ^a   Amato, M P ^d   Baum, K ^e   Buttmann, M ^f   Bayas, A ^g   Brassat, D ^h   Brochet, B ⁱ   Confavreux, C ^j   Edan, G ^k   Farkkila M ^l   Fredrikson, S ^m   Frontoni, M ⁿ   D'Hooghe, M ^o,p   Hutchinson, M ^q   De Keyser, J ^r   Kieseier, B C ^s   Kumpfel T ^t   Rio, J ^u   Polman, C ^v   Roullet, E ^w   Stolz, C ^x   Vass, K ^y   Wandinger, K P ^z   Kappos, L ^a   more..

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c Ospedale Civico Lugano   (Switzerland)

^d Kantonsspital Baselland Bruderholz ^*  (Switzerland)

^e UNIVERSITY OF FLORENCE   (Italy)

^f Klinik Hennigsdorf   (Germany)

^g UNIVERSITY OF WÜRZBURG   (Germany)

^h KLINIKUM AUGSBURG   (Germany)

ⁱ CHU PURPAN   (France)

^j BORDEAUX UNIVERSITY HOSPITAL   (France)

^k HÔPITAL NEUROLOGIQUE   (France)

^l PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^m UNIVERSITY OF HELSINKI   (Finland)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^o SAPIENZA UNIVERSITY OF ROME   (Italy)

^p National MS Center   (Belgium)

^q ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^r UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^s Department of Orthopedic Surgery   (Germany)

^t UNIVERSITY OF MUNICH   (Germany)

^u HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^v VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^w HÔPITAL TENON   (France)

^x PAREXEL INTERNATIONAL   (United States)

^y MEDICAL UNIVERSITY OF VIENNA   (Austria)

^z UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

more..

Author keywords

Disability; interferon beta; long term outcome; magnetic resonance imaging; multiple sclerosis; neutralizing antibodies; prognosis; randomized controlled trial; secondary progressive multiple sclerosis

Indexed keywords

INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE; PLACEBO; IMMUNOLOGIC FACTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; EUROPE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HISTORY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; OPEN STUDY; PREDICTIVE VALIDITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; TREATMENT OUTCOME; CLINICAL OBSERVATION; LONG TERM CARE; MORTALITY RATE; RELAPSE; CLINICAL TRIAL; DISABILITY; MORTALITY; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; TIME FACTOR;

ADULT; DISABILITY EVALUATION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; EUROPE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON BETA-1B; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIVARIATE ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84962595794     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515594440     Document Type: Article

References (35)

1. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: A geographically-based study. I. Clinical course and disability. Brain 1989; 112: 133-146.
2. Vukusic S, Confavreux C,. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 2003; 206: 135-137.
3. Confavreux C, Vukusic S, Adeleine P,. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain 2003; 126: 770-782.
4. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain 2010; 133: 1914-1929.
5. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991; 29: 53-62.
6. Nijeholt GJ, Van Walderveen MA, Castelijns JA, et al. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain 1998; 121: 687-697.
7. Filippi M, Preziosa P, Copetti M, et al. Gray matter damage predicts the accumulation of disability 13 years later in MS. Neurology 2013; 81: 1759-1767.
8. European Study Group on Interferon Beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-1497.
9. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: A combined analysis of the two trials. Neurology 2004; 63: 1779-1787.
10. Panitch H, Miller A, Paty D, et al. Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study. Neurology 2004; 63: 1788-1795.
11. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: Clinical results. Neurology 2001; 56: 1496-1504.
12. Andersen O, Elovaara I, Farkkila M, et al. Multicentre, randomised, double-blind, placebo-controlled, Phase III study of weekly, low-dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2004; 75: 706-710.
13. Goodin DS, Traboulsee A, Knappertz V, et al. Relationship between early clinical characteristics and long-term disability outcomes: 16-Year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83: 282-287.
14. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006; 67: 944-953.
15. Rudick RA, Cutter GR, Baier M, et al. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult Scler 2005; 11: 626-634.
16. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: Results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010; 16: 342-350.
17. Noseworthy JH,. How much can we learn from long-term extension trials in multiple sclerosis? Neurology 2006; 67: 930-931.
18. Marriott JJ, O'Connor PW,. Lessons learned from long-term multiple sclerosis treatment trials. Mult Scler 2010; 16: 1028-1030.
19. Molyneux PD, Barker GJ, Barkhof F, et al. Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. Neurology 2001; 57: 2191-2197.
20. Pittock SJ, Mayr WT, McClelland RL, et al. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurology 2004; 62: 601-606.
21. Bronnum-Hansen H, Koch-Henriksen N, Stenager E,. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004; 127: 844-850.
22. Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: A randomized cohort study 21 years after the start of the pivotal IFNbeta-1b trial. Neurology 2012; 78: 1315-1322.
23. Li DK, Held U, Petkau J, et al. MRI T2 lesion burden in multiple sclerosis: A plateauing relationship with clinical disability. Neurology 2006; 66: 1384-1389.
24. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain 2000; 123: 2256-2263.
25. Barkhof F, Van Waesberghe JH, Filippi M, et al. T(1) hypointense lesions in secondary progressive multiple sclerosis: Effect of interferon beta-1b treatment. Brain 2001; 124: 1396-1402.
26. Bermel RA, You X, Foulds P, et al. Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann Neurol 2013; 73: 95-103.
27. Rio J, Castillo J, Rovira A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009; 15: 848-853.
28. Polman C, Kappos L, White R, et al. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 2003; 60: 37-43.
29. Weinshenker BG, Rice GP, Noseworthy JH, et al. The natural history of multiple sclerosis: A geographically-based study. 3. Multivariate analysis of predictive factors and models of outcome. Brain 1991; 114: 1045-1056.
30. Confavreux C, Vukusic S, Adeleine P,. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain 2003; 126: 770-782.
31. Pittock SJ, Mayr WT, McClelland RL, et al. Change in MS-related disability in a population-based cohort: A 10-year follow-up study. Neurology 2004; 62: 51-59.
32. Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One 2013; 8: e75091.
33. Petzold A, De Boer JF, Schippling S, et al. Optical coherence tomography in multiple sclerosis: A systematic review and meta-analysis. Lancet Neurol 2010; 9: 921-932.
34. Fuhr P, Borggrefe-Chappuis A, Schindler C, et al. Visual and motor evoked potentials in the course of multiple sclerosis. Brain 2001; 124: 2162-2168.
35. Schlaeger R, Schindler C, Grize L, et al. Combined visual and motor evoked potentials predict multiple sclerosis disability after 20 years. Mult Scler 2014; 20: 1348-1354.